ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Discovery of a tricyclic farnesoid X receptor agonist HEC96719, a clinical candidate for treatment of non-alcoholic steatohepatitis

Cao, Shengtian; Yang, Xinye; Zhang, Zheng; Wu, Junwen; Chi, Bo; Chen, Hong; Yu, Jianghong; Feng, Shanshan; Xu, Yulin; Li, Jing; Zhang, Yingjun; Wang, Xiaojun*; Wang, Yan*南方医科大学; y
European Journal of Medicinal Chemistry2022-2-15DOI: 10.1016/j.ejmech.2021.114089
9被引6阅读
引用收藏
分享

摘要

Non-alcoholic fatty liver disease (NAFLD) is becoming the most predominant burden of chronic liver disease worldwide. Non-alcoholic steatohepatitis (NASH), the progressive form of NAFLD, can develop into cirrhosis and hepatocellular cancer. Unfortunately, current options for therapeutic treatment of NASH are very limited. Among multiple pathways in NASH, farnesoid X receptor (FXR), a nuclear bile acid receptor, is well-recognized as an important effective target. Here we report the synthesis and characterization of compound HEC96719 a novel tricyclic FXR agonist based on a prior high-affinity nonsteroidal molecule GW4064. HEC96719 exhibits excellent potency superior to GW4064 and obeticholic acid in in vitro and in vivo assays of FXR activation. It also shows higher FXR selectivity and more favorable tissue distribution dominantly in liver and intestine. Preclinical data on pharmacokinetic properties, efficacy, and safety profiles overall indicate that HEC96719 is a promising drug candidate for NASH treatment.

学科与关键词

关键词
Non-alcoholic steatohepatitisFarnesoid X receptor agonistChemical synthesisPharmacokinetic assayPharmacological assaySafety profilingDrug development
相关
加载中…
  • HEC96719, a novel tricyclic farnesoid X receptor agonist for treatment of non-alcoholic steatohepatitis: results of preclinical study and phase I trial
    Cao, Shengtian; Yang, Xinye; Dai, Liting; Li, Jing; Zhang, Ying Jun; Wang, Xiaojun; Wang, Yan
  • Discovery of LH10, a novel fexaramine-based FXR agonist for the treatment of liver disease
    Huang, Wanqiu; Cao, Zhijun; Wang, Wenxin; Yang, Zhongcheng; Jiao, Shixuan; Chen, Ya; Chen, Siliang; Zhang, Luyong*; Li, Zheng*Bioorganic Chemistry, 2024, 143: 107071.
  • Design, synthesis, and biological studies of novel sulfonamide derivatives as farnesoid X receptor agonists
    Wang, Wenxin; Cao, Zhijun; Yang, Zhongcheng; Chen, Ya; Yao, Huixin; Zhou, Danting; Ou, Peixin; Huang, Wanqiu; Jiao, Shixuan; Chen, Siliang; Chen, Lianru; Liu, Yuxia; Mao, Jianming; Xie, Jiayi; Xiang, Ruojing; Yang, Yuanqian; Chen, Yisi; Yang, Yonghong; Tan, Liyun; Tang, Haolong; Zhang, Luyong*; Li, Zheng*European Journal of Medicinal Chemistry, 2023, 258: 115614.
查看全部 →

发表信息

论文状态
公开发表
期刊
European Journal of Medicinal Chemistry
发表日期
2022-02-15
卷期
第 230 卷
页码
114089
DOI
10.1016/j.ejmech.2021.114089
语言
MULTI-LANGUAGE
期刊等级
1区
成果收录
SCIE
资助标注
National Science & Technology Major Project "Key New Drug Creation and Manufacturing Program", China [2018ZX09711002]; National Natural Science Foundation of China [82070589]

作者

  • C

    Cao, Shengtian (第一作者)

    southern med univ

  • Y

    Yang, Xinye

查看全部 13 位作者收起作者
  • Z

    Zhang, Zheng

  • W

    Wu, Junwen

  • C

    Chi, Bo

  • C

    Chen, Hong

  • Y

    Yu, Jianghong

  • F

    Feng, Shanshan

  • X

    Xu, Yulin

  • L

    Li, Jing

  • Z

    Zhang, Yingjun

  • W

    Wang, Xiaojun (通讯)

  • W

    Wang, Yan (通讯)

    southern med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417